Oct. 18, 2022

Why Clinical Trial Enrollment Sucks

Why Clinical Trial Enrollment Sucks

My guest today is Dr. Selin Kurnaz, Founder and CEO of Massive Bio, a company that is as impressive as it sounds. Its mission is to solve one of the single most critical scathing holes in healthcare: the "last mile" of clinical trial enrollment. What does that mean? You'll find out during our conversation, and rightfully so; the explanation will further deepen your pre-existing disdain for "the system." Selin is a no-BS serial entrepreneur who defines herself as a "non-status-quo businesswoman." whose sole purpose is to ensure every cancer patient gets access to a clinical trial; because only 20% of all patients that qualify for a clinical trial never actually fully enroll in that trial. And that is not OK. All that and more on the show today, let's get started.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

My guest today is Dr. Selin Kurnaz, Founder and CEO of Massive Bio, a company that is as impressive as it sounds. Its mission is to solve one of the single most critical scathing holes in healthcare: the "last mile" of clinical trial enrollment. What does that mean? You'll find out during our conversation, and rightfully so; the explanation will further deepen your pre-existing disdain for "the system." Selin is a no-BS serial entrepreneur who defines herself as a "non-status-quo businesswoman." whose sole purpose is to ensure every cancer patient gets access to a clinical trial; because only 20% of all patients that qualify for a clinical trial never actually fully enroll in that trial. And that is not OK. All that and more on the show today, let's get started.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.